AFT Pharmaceuticals (ASX:AFP) is in a red-hot position as we head straight into FY26’s fourth quarter in Australia, and founder and managing director Hartley Atkinson believes it’s only going to get better as the growing Oz-based multinational pharmaceutical company aims up for a $300M revenue target.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Speaking to HotCopper before Week 15 in a Watchlist interview, Atkinson said the company was “very confident” about reporting record sales.
“We’ve seen double-digit growth across literally every part of the business, and we’re seeing really good growth in the main Australian market,” Mr Atkinson told HotCopper in this update, “as well as internationally and in Asia.”
That’s been bumped up by an expansion into South Africa, where AFT Pharma has “literally started from zero,” as well as by the company’s strong early performance in the U.S. There, the company is closing several partnership deals to launch Maxigesic IV and Maxigesic Rapid sales in that mega-sized market.
You can watch the full AFP Watchlist interview in the browser above.
Join the discussion: See what HotCopper users are saying about AFT Pharmaceuticals Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.